Posted inAI Diabetes & Endocrinology news Specialties
Harnessing Digital Therapeutics to Improve Glycemic Control in Type 2 Diabetes: Insights from the BRIGHT Trial
	The BRIGHT trial evaluates AspyreRx, a digital cognitive behavioral therapy, for enhancing glycemic control in type 2 diabetes patients with residual hyperglycemia on stable medical therapy, focusing on efficacy, safety, and real-world applicability.
			 
				


















